Cayman Clozapine-D4; Purity- Greater Than Or Equal To 99% Deutera

Clozapine-d₄ is intended for use as an internal standard for the quantification of clozapine (Item Nos. | ) by GC- or LC-MS. Clozapine is a partial agonist at the serotonin (5-HT) receptor subtype 5-HT_1A (K_i = 180 nM).^, It also binds to 5-HT_2A, 5-HT_2C, 5-HT₃, 5-HT₆ and 5-HT₇ receptors (K_is = 3.3, 13, 110, 4, and 21 nM, respectively), as well as the histamine H₁ and α₁-adrenergic receptors (K_is = 2.1 and 23 nM, respectively). It does not bind to the 5-HT_1B receptor and has a lower affinity for dopamine receptors (K_is = 540, 150, and 360 nM for D_1-3, respectively). Clozapine induces the release of glutamate and D-serine, an agonist at the glycine site of the NMDA receptor, from astrocytes, and reduces the expression of astrocytic glutamate transporters. It reverses locomotor hyperactivity and deficits in prepulse inhibition of acoustic startle in a rat neonatal ventral hippocampal ibotenic lesion model of schizophrenia when administered at a dose of 2.5 mg/kg per day. Formulations containing clozapine have been used in the treatment of schizophrenia.

WARNING This product is not for human or veterinary use.